KMT2E-AS1: A Potential Drug Target and Biomarker (G100216545)
KMT2E-AS1: A Potential Drug Target and Biomarker
KMT2E-AS1, also known as KMT2E, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function have made it an attractive target for drug developers. In this article, we will explore the potential of KMT2E-AS1 as a drug target and biomarker.
The KMT2E gene
KMT2E is a gene that encodes a non-coding RNA molecule. It is located on chromosome 18q21 and has 295 amino acid residues. KMT2E is a splicing enhancer RNA, which means it helps to promote the production of RNA molecules that encode proteins.
KMT2E has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its role in these diseases has led to its potential as a drug target.
The potential benefits of KMT2E as a drug target
KMT2E has been shown to be involved in a variety of cellular processes that are important for human health. Its role in the regulation of gene expression, RNA processing, and protein synthesis makes it an attractive target for drugs that target these processes.
One of the potential benefits of KMT2E as a drug target is its potential to treat conditions that are currently unresponsive to traditional therapies. For example, KMT2E has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are currently treated with a limited number of drugs that offer significant improvements in quality of life. By targeting KMT2E, researchers hope to develop new treatments that can significantly improve the treatment outcomes for these conditions.
Another potential benefit of KMT2E as a drug target is its potential to be used in combination with other drugs. Because KMT2E is involved in a variety of cellular processes, it may be able to enhance the effectiveness of other drugs by targets that are not present in the treatment regimen.
The potential risks of KMT2E as a drug target
While KMT2E has the potential to be a drug target, there are also potential risks associated with its use. One of the biggest concerns is the potential for KMT2E to cause unintended side effects. The body's cells are very sensitive to changes in the levels of various molecules, including RNA. If KMT2E is used to treat conditions where it is known to cause significant side effects, researchers may need to carefully monitor the safety of the drug.
Another potential risk associated with KMT2E is its potential to have limited efficacy. While KMT2E has been shown to be involved in the development of various diseases, it may not be a effective treatment for all of these conditions. Researchers will need to carefully study the effects of KMT2E in order to determine its potential effectiveness as a drug.
The potential of KMT2E as a biomarker
In addition to its potential as a drug target, KMT2E has also been shown to be a potential biomarker. Its unique structure and function make it an attractive target for researchers who are interested in using it as a diagnostic or predictive tool.
One of the potential benefits of KMT2E as a biomarker is its ability to provide sensitive and reliable results. Unlike traditional biomarkers that may be affected by factors such as inflammation or disease, KMT2E has been shown to be consistently and reliably detected in a variety of samples, making it an attractive option for researchers who are looking for a reliable and sensitive tool for diagnosing or predicting disease.
Another potential benefit of KMT2E as a biomarker is its potential to be used in combination with other diagnostic tests. Because KMT2E is detectable in a variety of samples, it may be able
Protein Name: KMT2E Antisense RNA 1
More Common Targets
A2M | A2MP1 | A4GALT | ABAT | ABCA1 | ABCB1 | ABCB6 | ABCC5 | ABCC9 | ABCF2 | ABCG2 | ABHD11-AS1 | ABHD3 | ABI1 | ABI2 | ACAA1 | ACACA | ACAN | ACE | ACE2 | ACE3P | ACOT8 | ACP5 | ACSF3 | ACTA2-AS1 | ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | AOAH | AP1B1 | AP1G1 | AP1M2 | AP1S1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3S1 | AP4B1-AS1 | APBB1IP | APCDD1L | APELA | APLNR | APOBEC3A_B | APOBEC3B-AS1 | APOBEC3H | APOC4-APOC2 | APOOP2 | APPAT | APTR | AR | ARAP1-AS2 | ARFRP1 | ARHGAP19-SLIT1 | ARHGAP22-IT1 | ARHGAP26-AS1 | ARHGAP26-IT1 | ARHGAP31-AS1 | ARHGEF26-AS1 | ARHGEF33 | ARHGEF38 | ARHGEF38-IT1 | ARHGEF7-AS1 | ARID2 | ARID3A | ARL14EP | ARL15 | ARL17B | ARL2-SNX15 | ARL4A | ARL4C | ARLNC1 | ARMCX4 | ARMCX5-GPRASP2 | ARMCX6 | ARPC1B | ARPC2 | ARPC3 | ARPC4 | ARPC4-TTLL3 | ARPC5 | ARPIN-AP3S2 | ARRDC3-AS1 | ARX | ASAP1-IT2 | ASNSD1 | ASPN | ASTN2-AS1 | ASXL1 | ATAD2B | ATE1-AS1 | ATF4P4 | ATM | ATN1 | ATP11A-AS1 | ATP13A5-AS1 | ATP2A1-AS1 | ATP5PBP5 | ATP5PO | ATP6AP1 | ATP6AP2 | ATP6V0A1 | ATP6V0B | ATP6V0CP1 | ATP6V0E1P1 | ATP6V1FNB | ATP6V1G2 | ATP6V1G2-DDX39B | ATP7A | ATP7B | ATP8B1-AS1 | ATP9A | ATR | ATRX | B3GALT9 | B3GNT6 | BAALC-AS1 | BABAM2-AS1 | BACE1-AS | BANCR | BAX | BBS12 | BCAP31 | BCAR3-AS1 | BCAS2P2 | BCAS3 | BCL11A | BCL2 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L2-PABPN1 | BCO1 | BCRP7 | BECN1 | BEST2 | BHLHA15 | BHLHE40-AS1 | BICRA | BIVM | BIVM-ERCC5 | BLACAT1 | BLOC1S1-RDH5 | BLOC1S5-TXNDC5 | BMPER | BMPR1B-DT | BMS1P17 | BMS1P21 | BMS1P7 | BNC2 | BOK-AS1 | BOLA3-DT | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BPIFB5P | BRAF | BRCA1 | BRINP1 | BRWD1 | BSN-DT | BSPH1 | BSPRY | BTBD1 | BTBD16 | BTG4 | BTN2A3P | BTNL10P | BYSL | C10orf71 | C10orf71-AS1 | C10orf90 | C10orf95-AS1 | C11orf24 | C11orf71 | C11orf91 | C13orf46 | C16orf82 | C16orf95 | C17orf107 | C17orf99 | C18orf54 | C1orf68 | C1QBP | C1QL2 | C1QTNF1-AS1 | C1QTNF3-AMACR | C20orf181 | C21orf58 | C21orf62-AS1 | C21orf91 | C2CD4D | C2CD4D-AS1 | C4B_2 | C4orf46P3 | C5orf52